Search

Zentalis Pharmaceuticals Inc

Uždarymo kaina

2.75 -4.51

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.77

Max

3.06

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-42M

-78M

Pelnas, tenkantis vienai akcijai

-0.59

Darbuotojai

106

EBITDA

-42M

-77M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+185.71% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-44M

287M

Ankstesnė atidarymo kaina

7.26

Ankstesnė uždarymo kaina

2.75

Zentalis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-23 23:56; UTC

In after-market trading, Interactive Brokers Group Inc is roughly flat, with price fluctuations reflecting minimal movement since Wednesday's close.

2026-09-23 23:56; UTC

Correlated Moves

Allegiant Travel Co is trading modestly higher in after-market hours, recovering from earlier losses and currently positioned in the middle of its one-month trading range.

2026-09-23 23:56; UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026-09-23 23:56; UTC

Dow Inc saw a slight decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month range.

2026-09-23 23:55; UTC

Rush Street Interactive Inc. is trading roughly flat during after-market hours, following eight consecutive sessions with lower closes and remaining below its 20-day moving average.

2026-09-23 23:55; UTC

Endava PLC is seeing a slight decline in after-market trading, continuing a trend of lower daily closes and trading below its 20-day moving average.

2026-09-23 23:55; UTC

Delek US Holdings Inc is trading modestly higher during after-market hours, recovering from earlier declines while remaining below its 20-day moving average.

2026-09-23 23:55; UTC

Macro News

The U.S. Dollar Index is trading roughly flat, with macroeconomic developments highlighting oil supply from the Strait of Hormuz amid rising U.S. crude inventories.

2026-09-23 23:55; UTC

Cardinal Health Inc is trading modestly higher in after-market hours following slight fluctuations during the session, remaining below its 20-day moving average.

2026-09-23 23:52; UTC

Northrop Grumman Corp is declining in after-market trading, settling lower after briefly turning positive and remaining below its 20-day moving average.

2026-09-23 23:52; UTC

South Africa's Balance of Trade Data Release on September 30: Market Eyes Sustained Surplus Amid Mixed Economic Signals.

2026-09-23 23:52; UTC

Germany's Inflation Rate Expected to Remain Stable Ahead of September 30 Release Amid Geopolitical Tensions and Strong Manufacturing Activity

2026-09-23 23:52; UTC

Germany's Inflation Rate Release on September 30 Expected to Show Stability Amid Strong Manufacturing Growth and Geopolitical Tensions.

2026-09-23 23:52; UTC

Mixed Sentiment Ahead of U.S. New Home Sales Data Release Amidst Slowing Activity and Luxury Market Resilience

2026-09-23 23:52; UTC

New Home Sales Expected at 0.62 Million Amid Rising Prices and Cautious Market Sentiment

2026-09-23 23:52; UTC

Japan's Tankan Large Manufacturers Index set for release on September 30, amid mixed market sentiments influenced by global economic factors and rising interest rate concerns.

2026-09-23 23:51; UTC

Cleveland-Cliffs Inc has traded lower in after-market hours, pulling back from earlier highs while remaining above its 20-day moving average.

2026-09-23 23:51; UTC

Urban Outfitters Inc. is declining in after-market trading, falling significantly below its 20-day moving average and nearing the lower end of its one-month range.

2026-09-23 23:51; UTC

Guidewire Software Inc's shares are trading modestly higher in after-market hours, continuing a trend of gradual increases since Wednesday's close.

2026-09-23 23:51; UTC

Conagra Brands Inc is seeing modest declines in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026-09-23 23:51; UTC

Frontdoor Inc's shares advanced modestly in after-market trading, achieving nearly a 1% cumulative return since Wednesday's close, despite trading near the lower end of its range.

2026-09-23 23:51; UTC

Nu Holdings Ltd. saw a modest increase in after-market trading, recovering from a low point and marking a cumulative return of nearly 1%.

2026-09-23 23:51; UTC

West Pharmaceutical Services Inc is seeing a modest decline in after-market trading, positioned at the lower end of today's range but above its 20-day moving average.

2026-09-23 23:51; UTC

Cable One Inc is trading modestly higher in after-market hours, following a notable peak shortly after the regular session ended.

2026-09-23 23:51; UTC

Vertex Pharmaceuticals Inc saw a modest rise in after-market trading, recovering from a low return shortly after the market closed.

2026-09-23 23:46; UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

2026-09-23 23:46; UTC

Boyd Gaming Corp declined in after-market trading, moving from a slight gain to a loss, and is significantly below its 20-day moving average.

2026-09-23 23:46; UTC

Repligen Corp's stock declined in after-market trading, hitting its lowest point of the day after Wednesday's close, despite remaining above its 20-day moving average.

2026-09-23 23:46; UTC

CEVA Inc is trading modestly higher in after-market hours, maintaining strength above its 20-day moving average amid positive private sector activity indicators.

2026-09-23 23:46; UTC

Sirius XM Holdings Inc is down in after-market trading, marking four consecutive sessions of declines and remaining below its 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Zentalis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

185.71% į viršų

12 mėnesių prognozė

Vidutinis 8.8 USD  185.71%

Aukščiausias 11 USD

Žemiausias 5 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zentalis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

5

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.